Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 51, 2016 - Issue 11
Submit an article Journal homepage
503
Views
17
CrossRef citations to date
0
Altmetric
Original Article

Pirfenidone inhibits the proliferation of fibroblasts from patients with active Crohn’s disease

Sara-Irini KadirDepartment of Hepatology and Gastroenterology, Gastro-Immuno Research Laboratory (GIRL), Aarhus University Hospital, Aarhus, Denmark;
,
Tue Wenzel KragstrupDepartment of Biomedicine, Aarhus University, Aarhus, Denmark
,
Anders DigeDepartment of Hepatology and Gastroenterology, Gastro-Immuno Research Laboratory (GIRL), Aarhus University Hospital, Aarhus, Denmark;
,
Simon Kok JensenDepartment of Biomedicine, Aarhus University, Aarhus, Denmark
,
Jens Frederik DahlerupDepartment of Hepatology and Gastroenterology, Gastro-Immuno Research Laboratory (GIRL), Aarhus University Hospital, Aarhus, Denmark;
&
Jens KelsenDepartment of Hepatology and Gastroenterology, Gastro-Immuno Research Laboratory (GIRL), Aarhus University Hospital, Aarhus, Denmark; Correspondence[email protected]
Pages 1321-1325 | Received 28 Apr 2016, Accepted 28 Apr 2016, Published online: 16 May 2016

References

  • Burke JP, Mulsow JJ, O'Keane C, et al. Fibrogenesis in Crohn's disease. Am J Gastroenterol. 2007;102:439–448.
  • Louis E, Collard A, Oger AF, et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001;49:777–782.
  • Rieder F, Fiocchi C. Mechanisms of tissue remodeling in inflammatory bowel disease. Dig Dis. 2013;31:186–193.
  • Rogler G. New therapeutic avenues for treatment of fibrosis: can we learn from other diseases? Dig Dis. 2014;32:39–49.
  • Latella G, Sferra R, Speca S, et al. Can we prevent, reduce or reverse intestinal fibrosis in IBD? Eur Rev Med Pharmacol Sci. 2013;17:1283–1304.
  • Latella G, Rogler G, Bamias G, et al. Results of the 4th scientific workshop of the ECCO (I): pathophysiology of intestinal fibrosis in IBD. J Crohns Colitis. 2014;8:1147–1165.
  • Di Sabatino A, Jackson CL, Pickard KM, et al. Transforming growth factor beta signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures. Gut. 2009;58:777–789.
  • Schaefer CJ, Ruhrmund DW, Pan L, et al. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev. 2011;20:85–97.
  • Rieder F, Fiocchi C. Intestinal fibrosis in inflammatory bowel disease – current knowledge and future perspectives. J Crohns Colitis. 2008;2:279–290.
  • Armendariz-Borunda J, Islas-Carbajal MC, Meza-Garcia E, et al. A pilot study in patients with established advanced liver fibrosis using pirfenidone. Gut. 2006;55:1663–1665.
  • Cottin V, Maher T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev. 2015;24:58–64.
  • Macias-Barragan J, Sandoval-Rodriguez A, Navarro-Partida J, et al. The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair. 2010;3:16–27.
  • Pesce E, Struma E, Giri SN, et al. Antirheumatic effect of pirfenidone in a double blind clinical pilot trial in humans. Res Comm Mol Pathol Pharmacol. 2004;115-116:39–48.
  • Armendariz-Borunda J, Lyra-Gonzalez I, Medina-Preciado D, et al. A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients. Ann Plast Surg. 2012;68:22–28.
  • Grattendick KJ, Nakashima JM, Feng L, et al. Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro. Int Immunopharmacol. 2008;8:679–687.
  • Rieder F, de Bruyn JR, Pham BT, et al. Results of the 4th scientific workshop of the ECCO (Group II): markers of intestinal fibrosis in inflammatory bowel disease. J Crohns Colitis. 2014;8:1166–1178.
  • Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis. 2010;4:28–62.
  • Best WR, Becktel JM, Singleton JW Jr, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439–444.
  • Best WR. Predicting the Crohn's disease activity index from the Harvey-Bradshaw Index. Inflamma Bowel Dis. 2006;12:304–310.
  • Shi Q, Liu X, Bai Y, et al. In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion. PLoS One. 2011;6:e28134. DOI: 10.1371/journal.pone.0028134.
  • Makitalo L, Sipponen T, Karkkainen P, et al. Changes in matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinases (TIMP) expression profile in Crohn's disease after immunosuppressive treatment correlate with histological score and calprotectin values. Int J Colorectal Dis. 2009;24:1157–1167.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.